{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:54:16Z","timestamp":1784854456968,"version":"3.55.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ono Pharmacutical Co. Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","sleep.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine Clinics"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jsmc.2020.02.006","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T16:28:48Z","timestamp":1588696128000},"page":"177-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacologic Management of Excessive Daytime Sleepiness"],"prefix":"10.1016","volume":"15","author":[{"given":"Shinichi","family":"Takenoshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/sleep\/28.1.123","article-title":"The clinical use of the MSLT and MWT","volume":"28","author":"Arand","year":"2005","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.006_bib2","first-page":"438","article-title":"The relation between burnout and sleep disorders in medical students","volume":"38","author":"Pagnin","year":"2014","journal-title":"Acad Psychiatry"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.006_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2869.2010.00890.x","article-title":"Sleep disorders and work performance: findings from the 2008 National Sleep Foundation Sleep in America poll","volume":"20","author":"Swanson","year":"2011","journal-title":"J\u00a0Sleep Res"},{"issue":"Suppl 16","key":"10.1016\/j.jsmc.2020.02.006_bib4","first-page":"12","article-title":"Epidemiology of daytime sleepiness: definitions, symptomatology, and prevalence","volume":"65","author":"Young","year":"2004","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jsmc.2020.02.006_bib5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1186\/1471-2458-12-849","article-title":"Excessive daytime sleepiness assessed by the Epworth Sleepiness Scale and its association with health related quality of life: a population-based study in China","volume":"12","author":"Wu","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jsmc.2020.02.006_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jad.2016.08.039","article-title":"Longitudinal associations of hypersomnolence and depression in the Wisconsin sleep cohort study","volume":"207","author":"Plante","year":"2017","journal-title":"J\u00a0Affect Disord"},{"issue":"9","key":"10.1016\/j.jsmc.2020.02.006_bib7","doi-asserted-by":"crossref","first-page":"e1145","DOI":"10.4088\/JCP.14019tx1c","article-title":"Effects of excessive daytime sleepiness and fatigue on overall health and cognitive function","volume":"76","author":"Roth","year":"2015","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.jsmc.2020.02.006_bib8","doi-asserted-by":"crossref","first-page":"e0166262","DOI":"10.1371\/journal.pone.0166262","article-title":"Sleep apnea, sleep debt and daytime sleepiness are independently associated with road accidents. A cross-sectional study on truck drivers","volume":"11","author":"Garbarino","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jsmc.2020.02.006_bib9","first-page":"4215938","article-title":"A\u00a0practical approach to excessive daytime sleepiness: a focused review","volume":"2016","author":"Murray","year":"2016","journal-title":"Can Respir J"},{"issue":"17","key":"10.1016\/j.jsmc.2020.02.006_bib10","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1001\/jama.1931.02720430020006","article-title":"Symptomatic treatment for narcolepsy","volume":"96","author":"Doyle","year":"1931","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jsmc.2020.02.006_bib11","first-page":"704","article-title":"Pharmacotherapy in narcolepsy","volume":"21","author":"Akimoto","year":"1960","journal-title":"Dis Nerv Syst"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/archneur.1974.00490310092014","article-title":"On the treatment of rapid eye movement narcolepsy","volume":"30","author":"Guilleminault","year":"1974","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.006_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1600-0404.1975.tb05830.x","article-title":"Natural history, symptoms and treatment of the narcoleptic syndrome","volume":"52","author":"Parkes","year":"1975","journal-title":"Acta Neurol Scand"},{"issue":"27","key":"10.1016\/j.jsmc.2020.02.006_bib14","first-page":"1917","article-title":"[Narcolepsy]","volume":"26","author":"Passouant","year":"1976","journal-title":"Rev Prat"},{"key":"10.1016\/j.jsmc.2020.02.006_bib15","series-title":"International classification of sleep disorders","author":"ICSD-3","year":"2014"},{"issue":"2","key":"10.1016\/j.jsmc.2020.02.006_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jsmc.2015.02.001","article-title":"Kleine-levin syndrome","volume":"10","author":"Arnulf","year":"2015","journal-title":"Sleep Med Clin"},{"key":"10.1016\/j.jsmc.2020.02.006_bib17","series-title":"International classification of sleep disorders","author":"Medicine AAoS","year":"2014"},{"key":"10.1016\/j.jsmc.2020.02.006_bib18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ana.410350612","article-title":"The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort","volume":"35","author":"Hublin","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jsmc.2020.02.006_bib19","unstructured":"Tashiro T, Kanbayashi T, Hishikawa Y. An epidemiological study of narcolepsy in Japanese. Paper presented at: The 4th International Symposium on Narcolepsy. Tokyo, Japan, June 16\u201317, 1994. p. 13."},{"issue":"11","key":"10.1016\/j.jsmc.2020.02.006_bib20","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1212\/WNL.57.11.2029","article-title":"Age at onset of narcolepsy in two large populations of patients in France and Quebec","volume":"57","author":"Dauvilliers","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0301-0082(96)00070-6","article-title":"Pharmacological aspects of human and canine narcolepsy","volume":"52","author":"Nishino","year":"1997","journal-title":"Prog Neurobiol"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.006_bib22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/sleep\/32.3.382","article-title":"Daytime sleepiness and driving performance in patients with obstructive sleep apnea: comparison of the MSLT, the MWT, and a simulated driving task","volume":"32","author":"Pizza","year":"2009","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/sleep\/28.1.113","article-title":"Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test","volume":"28","author":"Littner","year":"2005","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.006_bib24","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1378\/chest.08-0822","article-title":"Multiple sleep latency test and maintenance of wakefulness test","volume":"134","author":"Sullivan","year":"2008","journal-title":"Chest"},{"issue":"27","key":"10.1016\/j.jsmc.2020.02.006_bib25","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jsmc.2020.02.006_bib26","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/S1388-2457(03)00203-7","article-title":"Clinical aspects and pathophysiology of narcolepsy","volume":"114","author":"Dauvilliers","year":"2003","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.jsmc.2020.02.006_bib27","series-title":"Narcolepsy syndrome. Principles and Practice of Sleep Medicine","first-page":"549","author":"Guilleminault","year":"1994"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.006_bib28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1399-0039.1984.tb02144.x","article-title":"HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive","volume":"24","author":"Juji","year":"1984","journal-title":"Tissue Antigens"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.006_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/sleep\/17.3.265","article-title":"Stability of cataplexy over several months\u2013information for the design of therapeutic trials","volume":"17","author":"Gelb","year":"1994","journal-title":"Sleep"},{"key":"10.1016\/j.jsmc.2020.02.006_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0013-4694(76)90210-8","article-title":"Sleep satiation in narcoleptic patients","volume":"41","author":"Hishikawa","year":"1976","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"10.1016\/j.jsmc.2020.02.006_bib31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0013-4694(88)90145-9","article-title":"Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched control","volume":"70","author":"Broughton","year":"1988","journal-title":"Electroencephalogr Clin Neurophysiol"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib32","first-page":"78","article-title":"Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption","volume":"13","author":"Montplaisir","year":"1978","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jsmc.2020.02.006_bib33","series-title":"Sleep \u201984","first-page":"380","article-title":"Comparison of sleep parameters in narcoleptics with and without periodic movements of sleep","author":"Godbout","year":"1985"},{"key":"10.1016\/j.jsmc.2020.02.006_bib34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/sleep\/7.2.115","article-title":"Nocturnal REM latency and sleep disturbance in narcolepsy","volume":"7","author":"Mosko","year":"1984","journal-title":"Sleep"},{"key":"10.1016\/j.jsmc.2020.02.006_bib35","first-page":"337","article-title":"Zur\u00a0Einsch\u00e4tzung des Behinderungsgrades bei Narkolepsie","volume":"55","author":"Mayer","year":"1993","journal-title":"Gesundheitswesen"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ana.410320103","article-title":"Motor dyscontrol in narcolepsy: Rapid-Eye-Movement (REM) sleep without atonia and REM sleep behavior disorder","volume":"32","author":"Schenck","year":"1992","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/sleep\/9.1.250","article-title":"Sleep apnea in narcolepsy","volume":"9","author":"Chokroverty","year":"1986","journal-title":"Sleep"},{"key":"10.1016\/j.jsmc.2020.02.006_bib38","series-title":"Narcolepsy","year":"1976"},{"key":"10.1016\/j.jsmc.2020.02.006_bib39","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1749-6632.1988.tb27056.x","article-title":"Narcolepsy and HLA in the Japanese","volume":"540","author":"Juji","year":"1988","journal-title":"Ann N Y Acad Sci"},{"issue":"9197","key":"10.1016\/j.jsmc.2020.02.006_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","article-title":"Hypocretin (orexin) deficiency in human narcolepsy","volume":"355","author":"Nishino","year":"2000","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jsmc.2020.02.006_bib41","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","article-title":"The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias","volume":"59","author":"Mignot","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jsmc.2020.02.006_bib42","series-title":"Diagnostic and coding manual","first-page":"38","article-title":"ICSD-2-International classification of sleep disorders","author":"ICSD-2","year":"2005"},{"issue":"11","key":"10.1016\/j.jsmc.2020.02.006_bib43","first-page":"1012","article-title":"HLA DQB1\u22170602 is associated with cataplexy in 509\u00a0narcoleptic patients","volume":"20","author":"Mignot","year":"1997","journal-title":"Sleep"},{"issue":"11","key":"10.1016\/j.jsmc.2020.02.006_bib44","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1212\/WNL.62.11.2137","article-title":"A\u00a0monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1","volume":"62","author":"Dauvilliers","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.006_bib45","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1006\/nbdi.2001.0389","article-title":"Hypocretin levels in sporadic and familial cases of canine narcolepsy","volume":"8","author":"Ripley","year":"2001","journal-title":"Neurobiol Dis"},{"issue":"8","key":"10.1016\/j.jsmc.2020.02.006_bib46","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/sleep\/32.8.993","article-title":"Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy","volume":"32","author":"Thannickal","year":"2009","journal-title":"Sleep"},{"issue":"8 Suppl","key":"10.1016\/j.jsmc.2020.02.006_bib47","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1093\/sleep\/17.suppl_8.S97","article-title":"Non-pharmacological approaches to the treatment of narcolepsy","volume":"17","author":"Garma","year":"1994","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib48","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/sleep\/9.1.194","article-title":"Alerting effects of naps in patients with narcolepsy","volume":"9","author":"Roehrs","year":"1986","journal-title":"Sleep"},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.006_bib49","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/01376517-198412000-00009","article-title":"Problems and coping strategies identified by narcoleptic patients","volume":"16","author":"Rogers","year":"1984","journal-title":"J\u00a0Neurosurg Nurs"},{"issue":"12","key":"10.1016\/j.jsmc.2020.02.006_bib50","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","article-title":"Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin","volume":"30","author":"Morgenthaler","year":"2007","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.006_bib51","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11940-011-0137-6","article-title":"Recent advances in the treatment of narcolepsy","volume":"13","author":"Hirai","year":"2011","journal-title":"Curr Treat Options Neurol"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.006_bib52","first-page":"352","article-title":"Narcolepsy and its treatment with stimulants. ASDA standards of practice","volume":"17","author":"Mitler","year":"1994","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.006_bib53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/sleep\/14.3.218","article-title":"Relative efficacy of drugs for the treatment of sleepiness in narcolepsy","volume":"14","author":"Mitler","year":"1991","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/sleep\/20.1.28","article-title":"Compliance with stimulant medications in patients with narcolepsy","volume":"20","author":"Rogers","year":"1997","journal-title":"Sleep"},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.006_bib55","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/sleep\/28.6.667","article-title":"Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study","volume":"28","author":"Auger","year":"2005","journal-title":"Sleep"},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.006_bib56","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1358\/dot.2008.44.5.1195861","article-title":"Armodafinil for excessive daytime sleepiness","volume":"44","author":"Nishino","year":"2008","journal-title":"Drugs Today (Barc)"},{"issue":"9","key":"10.1016\/j.jsmc.2020.02.006_bib57","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/11315280-000000000-00000","article-title":"Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies","volume":"29","author":"Darwish","year":"2009","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ana.410430115","article-title":"Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group","volume":"43","year":"1998","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.006_bib59","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1212\/WNL.54.5.1166","article-title":"Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group","volume":"54","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.006_bib60","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1185\/030079906X100050","article-title":"The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy","volume":"22","author":"Harsh","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jsmc.2020.02.006_bib61","unstructured":"United States Department of Justice. Drug Enforcement Administration. Drug Scheduling. Available at: https:\/\/www.dea.gov\/druginfo\/ds.shtml. Accessed February 10, 2017."},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.006_bib62","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5664\/jcsm.26970","article-title":"Evaluation of the safety of modafinil for treatment of excessive sleepiness","volume":"3","author":"Roth","year":"2007","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.jsmc.2020.02.006_bib63","unstructured":"U.S. Food & Drug Administration. Drug Safety. Medication Guide. Available at: http:\/\/www.fda.gov\/downloads\/drugs\/drugsafety\/ucm231722.pdf. Accessed February 11, 2017."},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.006_bib64","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00002826-200309000-00009","article-title":"Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy","volume":"26","author":"Schwartz","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jsmc.2020.02.006_bib65","unstructured":"Cephalon, Inc. FDA approval of NUVIGIL. Available at: https:\/\/www.sec.gov\/Archives\/edgar\/data\/873364\/000110465907048203\/a07-16834_1ex99d1.htm. Accessed February 11, 2017."},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.006_bib66","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/sleep\/17.5.436","article-title":"Modafinil binds to the dopamine uptake carrier site with low affinity","volume":"17","author":"Mignot","year":"1994","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib67","first-page":"49","article-title":"Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants","volume":"1","author":"Nishino","year":"1998","journal-title":"Sleep Res Online"},{"issue":"1\u20133","key":"10.1016\/j.jsmc.2020.02.006_bib68","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2007.03.044","article-title":"Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants","volume":"568","author":"Dopheide","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.006_bib69","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1523\/JNEUROSCI.21-05-01787.2001","article-title":"Dopaminergic role in stimulant-induced wakefulness","volume":"21","author":"Wisor","year":"2001","journal-title":"J\u00a0Neurosci"},{"issue":"34","key":"10.1016\/j.jsmc.2020.02.006_bib70","doi-asserted-by":"crossref","first-page":"8462","DOI":"10.1523\/JNEUROSCI.1819-08.2008","article-title":"Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil","volume":"28","author":"Qu","year":"2008","journal-title":"J\u00a0Neurosci"},{"issue":"11","key":"10.1016\/j.jsmc.2020.02.006_bib71","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/jama.2009.351","article-title":"Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications","volume":"301","author":"Volkow","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.006_bib72","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1212\/WNL.9.3.171","article-title":"Treatment of narcolepsy with ritalin","volume":"9","author":"Yoss","year":"1959","journal-title":"Neurology"},{"key":"10.1016\/j.jsmc.2020.02.006_bib73","series-title":"Neurochemistry of amphetamine, in psychopharmacology, toxicology and abuse","first-page":"81","author":"Kuczenski","year":"1994"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.006_bib74","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hup.579","article-title":"Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects","volume":"19","author":"Leonard","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.jsmc.2020.02.006_bib75","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-0348-8171-5_4","article-title":"The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate","volume":"59","author":"Schenk","year":"2002","journal-title":"Prog Drug Res"},{"issue":"14","key":"10.1016\/j.jsmc.2020.02.006_bib76","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp068049","article-title":"ADHD drugs and cardiovascular risk","volume":"354","author":"Nissen","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.jsmc.2020.02.006_bib77","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1056\/NEJMoa1110212","article-title":"ADHD drugs and serious cardiovascular events in children and\u00a0young adults","volume":"365","author":"Cooper","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0317167100119304","article-title":"The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate","volume":"6","author":"Broughton","year":"1979","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib79","first-page":"42","article-title":"A\u00a0randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy","volume":"25","year":"2002","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib80","first-page":"31","article-title":"A\u00a012-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy","volume":"26","year":"2003","journal-title":"Sleep"},{"issue":"2","key":"10.1016\/j.jsmc.2020.02.006_bib81","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.sleep.2003.11.002","article-title":"Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy","volume":"5","year":"2004","journal-title":"Sleep Med"},{"issue":"1 Pt 2","key":"10.1016\/j.jsmc.2020.02.006_bib82","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/sleep\/9.1.285","article-title":"Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings","volume":"9","author":"Mamelak","year":"1986","journal-title":"Sleep"},{"issue":"9","key":"10.1016\/j.jsmc.2020.02.006_bib83","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.sleep.2014.04.020","article-title":"Impact of acute administration of sodium oxybate on nocturnal sleep polysomnography and on multiple sleep latency test in narcolepsy with cataplexy","volume":"15","author":"Plazzi","year":"2014","journal-title":"Sleep Med"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.006_bib84","first-page":"232","article-title":"Love potion number 8 1\/2. Gamma-hydroxybutyrate poisoning","volume":"54","author":"Mack","year":"1993","journal-title":"N\u00a0C Med J"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib85","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tips.2003.11.001","article-title":"From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid","volume":"25","author":"Wong","year":"2004","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0376-8716(00)00191-5","article-title":"GHB: a new and novel drug of abuse","volume":"63","author":"Nicholson","year":"2001","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"10.1016\/j.jsmc.2020.02.006_bib87","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/sleep\/29.7.939","article-title":"Sodium oxybate improves excessive daytime sleepiness in narcolepsy","volume":"29","author":"Black","year":"2006","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.006_bib88","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/00023210-200721040-00007","article-title":"Sodium oxybate: a review of its use in the management of narcolepsy","volume":"21","author":"Robinson","year":"2007","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.006_bib89","doi-asserted-by":"crossref","first-page":"451","DOI":"10.5664\/jcsm.2048","article-title":"Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis","volume":"8","author":"Alshaikh","year":"2012","journal-title":"J\u00a0Clin Sleep Med"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.006_bib90","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11940-015-0347-4","article-title":"Update on therapy for narcolepsy","volume":"17","author":"Thorpy","year":"2015","journal-title":"Curr Treat Options Neurol"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.006_bib91","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00265954","article-title":"Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers","volume":"45","author":"Palatini","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.006_bib92","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5664\/jcsm.27549","article-title":"Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion","volume":"5","author":"Wang","year":"2009","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.jsmc.2020.02.006_bib93","unstructured":"Administration tUSFaD. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm332408.htm. Accessed February 9, 2017."},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jsmc.2016.10.013","article-title":"Hypersomnia: evaluation, treatment, and social and economic aspects","volume":"12","author":"Saini","year":"2017","journal-title":"Sleep Med Clin"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.006_bib95","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/med.21382","article-title":"Mechanisms for the specific properties of gamma-hydroxybutyrate in brain","volume":"36","author":"Maitre","year":"2016","journal-title":"Med Res Rev"},{"issue":"12","key":"10.1016\/j.jsmc.2020.02.006_bib96","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2165\/00023210-200620120-00004","article-title":"\u03b3-hydroxybutyrate\/sodium oxybate","volume":"20","author":"Pardi","year":"2006","journal-title":"CNS drugs"},{"issue":"12","key":"10.1016\/j.jsmc.2020.02.006_bib97","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1096\/fj.02-0846fje","article-title":"Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB)","volume":"17","author":"Andriamampandry","year":"2003","journal-title":"Faseb J"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.006_bib98","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0306-4522(98)00600-9","article-title":"Locus coeruleus neurons: cessation of activity during cataplexy","volume":"91","author":"Wu","year":"1999","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.006_bib99","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/0269881115573807","article-title":"GHB for cataplexy: possible mode of action","volume":"29","author":"Szabadi","year":"2015","journal-title":"J\u00a0Psychopharmacol"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(02)00032-X","article-title":"CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture","volume":"110","author":"Nishino","year":"2002","journal-title":"Psychiatry Res"},{"issue":"Suppl","key":"10.1016\/j.jsmc.2020.02.006_bib101","first-page":"A241","article-title":"Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin\/ataxin-3 narcoleptic mice","volume":"27","author":"Shiba","year":"2004","journal-title":"Sleep"},{"issue":"8","key":"10.1016\/j.jsmc.2020.02.006_bib102","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.bcp.2007.01.002","article-title":"The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders","volume":"73","author":"Parmentier","year":"2007","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib103","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","article-title":"An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-\/- mice and patients","volume":"30","author":"Lin","year":"2008","journal-title":"Neurobiol Dis"},{"issue":"11","key":"10.1016\/j.jsmc.2020.02.006_bib104","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","article-title":"Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial","volume":"12","author":"Dauvilliers","year":"2013","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.jsmc.2020.02.006_bib105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00965695","article-title":"Analogs of thyrotropin-releasing hormone (TRH): receptor affinities in brains, spinal cords, and pituitaries of different species","volume":"16","author":"Sharif","year":"1991","journal-title":"Neurochem Res"},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.006_bib106","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.sleep.2014.01.021","article-title":"Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review","volume":"15","author":"Leu-Semenescu","year":"2014","journal-title":"Sleep Med"},{"key":"10.1016\/j.jsmc.2020.02.006_bib107","first-page":"159","article-title":"Treatment paradigms for cataplexy in narcolepsy: past, present, and future","volume":"7","author":"Swick","year":"2015","journal-title":"Nat Sci Sleep"},{"key":"10.1016\/j.jsmc.2020.02.006_bib108","doi-asserted-by":"crossref","first-page":"212290","DOI":"10.7573\/dic.212290","article-title":"Antidepressant efficacy and side-effect burden: a quick guide for clinicians","volume":"4","author":"Santarsieri","year":"2015","journal-title":"Drugs Context"},{"issue":"Suppl 4","key":"10.1016\/j.jsmc.2020.02.006_bib109","first-page":"55","article-title":"Depression, sleep, and antidepressants","volume":"59","author":"Thase","year":"1998","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jsmc.2020.02.006_bib110","series-title":"Narkolepsie und hypersomnie","author":"Roth","year":"1962"},{"issue":"Pt 8","key":"10.1016\/j.jsmc.2020.02.006_bib111","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/brain\/120.8.1423","article-title":"Idiopathic hypersomnia. A series of 42 patients","volume":"120","author":"Bassetti","year":"1997","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib112","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/s1389-9457(02)00191-0","article-title":"The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A)","volume":"4","author":"Bassetti","year":"2003","journal-title":"Sleep Med"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.006_bib113","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2869.2010.00824.x","article-title":"Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepiness","volume":"19","author":"Vernet","year":"2010","journal-title":"J\u00a0Sleep Res"},{"key":"10.1016\/j.jsmc.2020.02.006_bib114","series-title":"International classification of sleep disorders: diagnostic and coding manual","year":"2014"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib115","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/jsr.12201","article-title":"Modafinil in the treatment of idiopathic hypersomnia without long sleep time\u2013a randomized, double-blind, placebo-controlled study","volume":"24","author":"Mayer","year":"2015","journal-title":"J\u00a0Sleep Res"},{"key":"10.1016\/j.jsmc.2020.02.006_bib116","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.smrv.2015.08.007","article-title":"Idiopathic hypersomnia","volume":"29","author":"Billiard","year":"2016","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.jsmc.2020.02.006_bib117","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.sleep.2015.10.005","article-title":"Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review","volume":"17","author":"Leu-Semenescu","year":"2016","journal-title":"Sleep Med"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.006_bib118","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.smrv.2005.03.004","article-title":"Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin\/orexin system","volume":"9","author":"Nishino","year":"2005","journal-title":"Sleep Med Rev"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.006_bib119","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5664\/jcsm.26856","article-title":"Sleep disorders in chronic traumatic brain injury","volume":"3","author":"Verma","year":"2007","journal-title":"J\u00a0Clin Sleep Med"},{"issue":"7","key":"10.1016\/j.jsmc.2020.02.006_bib120","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.sleep.2012.04.006","article-title":"Prevalence of sleep disturbances, disorders, and problems following traumatic brain injury: a meta-analysis","volume":"13","author":"Mathias","year":"2012","journal-title":"Sleep Med"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib121","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1212\/01.wnl.0000167605.02541.f2","article-title":"Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury","volume":"65","author":"Baumann","year":"2005","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.jsmc.2020.02.006_bib122","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1212\/WNL.0b013e3181fd62a2","article-title":"Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury","volume":"75","author":"Kaiser","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib123","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.HTR.0000308721.77911.ea","article-title":"A\u00a0randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury","volume":"23","author":"Jha","year":"2008","journal-title":"J\u00a0Head Trauma Rehabil"},{"issue":"11","key":"10.1016\/j.jsmc.2020.02.006_bib124","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.5664\/jcsm.4196","article-title":"Armodafinil for the treatment of excessive sleepiness associated with mild or moderate closed traumatic brain injury: a 12-week, randomized, double-blind study followed by a 12-month open-label extension","volume":"10","author":"Menn","year":"2014","journal-title":"J\u00a0Clin Sleep Med"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jns.2003.08.010","article-title":"Snoring and excessive daytime sleepiness in Parkinson\u2019s disease","volume":"217","author":"Braga-Neto","year":"2004","journal-title":"J\u00a0Neurol Sci"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.006_bib126","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1212\/01.wnl.0000233980.25978.9d","article-title":"Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?","volume":"67","author":"Gjerstad","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib127","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/mds.21727","article-title":"Nighttime sleep problems and daytime sleepiness in Parkinson\u2019s disease","volume":"23","author":"Verbaan","year":"2008","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.jsmc.2020.02.006_bib128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mds.10390","article-title":"Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson\u2019s disease","volume":"18","author":"Adler","year":"2003","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.jsmc.2020.02.006_bib129","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/sleep\/25.8.62","article-title":"Modafinil for the treatment of daytime sleepiness in Parkinson\u2019s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial","volume":"25","author":"Hogl","year":"2002","journal-title":"Sleep"},{"issue":"12","key":"10.1016\/j.jsmc.2020.02.006_bib130","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/jnnp.2005.065870","article-title":"Modafinil for\u00a0daytime somnolence in Parkinson\u2019s disease: double blind, placebo controlled parallel trial","volume":"76","author":"Ondo","year":"2005","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"10","key":"10.1016\/j.jsmc.2020.02.006_bib131","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archneur.65.10.1337","article-title":"Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study","volume":"65","author":"Ondo","year":"2008","journal-title":"Arch Neurol"},{"issue":"7\u20138","key":"10.1016\/j.jsmc.2020.02.006_bib132","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00018-003-3269-3","article-title":"Caffeine as a psychomotor stimulant: mechanism of action","volume":"61","author":"Fisone","year":"2004","journal-title":"Cell Mol Life Sci"},{"issue":"5316","key":"10.1016\/j.jsmc.2020.02.006_bib133","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.276.5316.1265","article-title":"Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness","volume":"276","author":"Porkka-Heiskanen","year":"1997","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/0265203021000007840","article-title":"Effects of caffeine on human health","volume":"20","author":"Nawrot","year":"2003","journal-title":"Food Addit Contam"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0278-6915(95)00093-3","article-title":"Caffeine consumption","volume":"34","author":"Barone","year":"1996","journal-title":"Food Chem Toxicol"},{"issue":"13","key":"10.1016\/j.jsmc.2020.02.006_bib136","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1073\/pnas.0400590101","article-title":"Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice","volume":"101","author":"Mieda","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.jsmc.2020.02.006_bib137","first-page":"586","article-title":"The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy","volume":"18","author":"Schatzberg","year":"2004","journal-title":"J\u00a0Vet Intern Med"},{"issue":"9","key":"10.1016\/j.jsmc.2020.02.006_bib138","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/sleep\/32.9.1127","article-title":"Orexin neurons are necessary for the circadian control of REM sleep","volume":"32","author":"Kantor","year":"2009","journal-title":"Sleep"},{"issue":"52","key":"10.1016\/j.jsmc.2020.02.006_bib139","doi-asserted-by":"crossref","first-page":"14239","DOI":"10.1523\/JNEUROSCI.3878-07.2007","article-title":"Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates","volume":"27","author":"Deadwyler","year":"2007","journal-title":"J\u00a0Neurosci"},{"issue":"20","key":"10.1016\/j.jsmc.2020.02.006_bib140","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1021\/acs.jmedchem.5b00988","article-title":"Design and synthesis of non-peptide, selective orexin receptor 2 agonists","volume":"58","author":"Nagahara","year":"2015","journal-title":"J\u00a0Med Chem"},{"issue":"10","key":"10.1016\/j.jsmc.2020.02.006_bib141","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.sleep.2011.06.015","article-title":"Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy","volume":"12","author":"Baier","year":"2011","journal-title":"Sleep Med"},{"issue":"8","key":"10.1016\/j.jsmc.2020.02.006_bib142","first-page":"1119","article-title":"Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy","volume":"31","author":"Mishima","year":"2008","journal-title":"Sleep"},{"issue":"7","key":"10.1016\/j.jsmc.2020.02.006_bib143","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/sleep\/33.7.869","article-title":"Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy","volume":"33","author":"Kawashima","year":"2010","journal-title":"Sleep"},{"issue":"16","key":"10.1016\/j.jsmc.2020.02.006_bib144","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1212\/WNL.0b013e3181bd1344","article-title":"Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment","volume":"73","author":"Dauvilliers","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.006_bib145","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ana.20339","article-title":"Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset","volume":"56","author":"Dauvilliers","year":"2004","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.006_bib146","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1073\/pnas.80.6.1735","article-title":"Prostaglandin D2, a cerebral sleep-inducing substance in rats","volume":"80","author":"Ueno","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib147","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.coph.2006.09.004","article-title":"Prostaglandins and adenosine in the regulation of sleep and wakefulness","volume":"7","author":"Huang","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jsmc.2020.02.006_bib148","first-page":"1372","article-title":"Narcolepsy increased L-PGDS (beta-trace) levels correlate with excessive daytime sleepiness but not with cataplexy","volume":"252","author":"Jordan","year":"2005","journal-title":"J\u00a0Neurol"},{"issue":"Part A","key":"10.1016\/j.jsmc.2020.02.006_bib149","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.neuropharm.2016.07.013","article-title":"Wake-promoting effects of ONO-4127Na, a prostaglandin DP1 receptor antagonist, in hypocretin\/orexin deficient narcoleptic mice","volume":"110","author":"Sagawa","year":"2016","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.jsmc.2020.02.006_bib150","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0893-133X(99)00159-1","article-title":"Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy","volume":"23","author":"Riehl","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"5591","key":"10.1016\/j.jsmc.2020.02.006_bib151","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/265242a0","article-title":"Excitatory action of TRH on spinal motoneurones","volume":"265","author":"Nicoll","year":"1977","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.jsmc.2020.02.006_bib152","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1523\/JNEUROSCI.17-16-06401.1997","article-title":"Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy","volume":"17","author":"Nishino","year":"1997","journal-title":"J\u00a0Neurosci"},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.006_bib153","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/j.1471-4159.1982.tb08018.x","article-title":"Thyrotrophin-releasing hormone analogues increase dopamine release from slices of rat brain","volume":"39","author":"Sharp","year":"1982","journal-title":"J\u00a0Neurochem"},{"issue":"2","key":"10.1016\/j.jsmc.2020.02.006_bib154","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/1096-9861(20001211)428:2<319::AID-CNE10>3.0.CO;2-9","article-title":"Expression of thyrotropin-releasing hormone receptor 2 (TRH-R2) in the central nervous system of rats","volume":"428","author":"Heuer","year":"2000","journal-title":"J\u00a0Comp Neurol"},{"issue":"448","key":"10.1016\/j.jsmc.2020.02.006_bib155","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/248528a0","article-title":"Enhancement of cerebral noradrenaline turnover by thyrotropin-releasing hormone","volume":"248","author":"Keller","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.jsmc.2020.02.006_bib156","unstructured":"Broberger C. Neurotransmitters switching the thalamus between sleep and arousal: functional effects and cellular mechanism. New Frontiers in Neuroscience Research. Showa University International Symposium for Life Science. 1st Annual Meeting Showa University Kamijo Hall. Tokyo, August 31, 2004."},{"issue":"6","key":"10.1016\/j.jsmc.2020.02.006_bib157","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/sleep\/28.6.754","article-title":"Emerging therapies in narcolepsy-cataplexy","volume":"28","author":"Mignot","year":"2005","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/j.jsmc.2020.02.006_bib158","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0893-133X(00)00140-8","article-title":"Sulpiride, a D2\/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy","volume":"23","author":"Okura","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jsmc.2020.02.006_bib159","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/B978-0-444-52007-4.00007-2","article-title":"Narcolepsy and cataplexy","volume":"99","author":"Nishino","year":"2011","journal-title":"Handb Clin Neurol"}],"container-title":["Sleep Medicine Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556407X20300175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556407X20300175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:02:28Z","timestamp":1761562948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556407X20300175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":159,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1556407X20300175"],"URL":"https:\/\/doi.org\/10.1016\/j.jsmc.2020.02.006","relation":{},"ISSN":["1556-407X"],"issn-type":[{"value":"1556-407X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Management of Excessive Daytime Sleepiness","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsmc.2020.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}